Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 4/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445902 | 0.84 | FGFR1 (0.50) | GSK3BAXLJAK2PDPK1FGFR1 | |
| SCHEMBL118573 | 0.81 | JAK2 (0.64) | GSK3BAXLHTR2AHTR2CHTR2B | |
| SCHEMBL7571499 | 0.76 | GSK3B (0.51) | GSK3BAXLHTR2AHTR2CHTR2B | |
| SCHEMBL266855 | 0.76 | GSK3B (0.56) | GSK3BAXLHTR2AHTR2CHTR2B | |
| SCHEMBL29644057 | 0.76 | GSK3B (0.56) | GSK3BAXLHTR2AHTR2CHTR2B | |
| SCHEMBL762275 | 0.76 | GSK3B (0.51) | GSK3BAXLHTR2AHTR2CHTR2B | |
| SCHEMBL2467763 | 0.76 | JAK2 (0.53) | GSK3BAXLHTR2AHTR2CHTR2B | |
| SCHEMBL2300691 | 0.76 | PDPK1 (0.63) | GSK3BAXLHTR2AHTR2CHTR2B | |
| SCHEMBL759158 | 0.76 | GSK3B (0.51) | GSK3BAXLHTR2AHTR2CHTR2B | |
| SCHEMBL29644051 | 0.76 | GSK3B (0.51) | GSK3BAXLHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | RAPPORT THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12145934-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-19 | — | — | US | disclosed |
| US-12139485-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-12 | — | — | US | disclosed |
| US-20230110576-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-13 | — | — | US | disclosed |
| US-20230114165-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-13 | — | — | US | disclosed |
| EP-4144736-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
| US-11312712-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-04-26 | — | — | US | disclosed |
| EP-3901153-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-10-27 | — | — | EP | disclosed |
| US-20210284641-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-16 | — | — | US | disclosed |
| EP-1773786-B1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-26 | — | — | EP | disclosed |
| WO-2016176460-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| CN-100369899-C | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | CN | disclosed |
| CN-1642922-A | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2005-07-20 | — | — | CN | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284641-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | GSK3B 2690/4885AXL 268/4885HTR2A 549/4885 |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | GSK3B 75/4885AXL 462/4885HTR2A 3852/4885 |
| US-12139485-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | GSK3B 2690/4885AXL 268/4885HTR2A 549/4885 |
| US-12145934-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | GSK3B 2690/4885AXL 268/4885HTR2A 549/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | GSK3B 100/4885AXL 630/4885HTR2A 4109/4885 |
| US-20230110576-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | GSK3B 2690/4885AXL 268/4885HTR2A 549/4885 |
| US-11312712-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | GSK3B 2690/4885AXL 268/4885HTR2A 549/4885 |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | GSK3B 2690/4885AXL 268/4885HTR2A 549/4885 |
| US-20230114165-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | GSK3B 2690/4885AXL 268/4885HTR2A 549/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | GSK3B 2720/4885AXL 275/4885HTR2A 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.